Wednesday, November 18, 2009

Basilea's Toctino Receives Marketing Authorization in Canada

November 18, 2009 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has obtained regulatory approval from Health Canada.

The details can be read here.

No comments: